News

There are many ways one could end up with $1 million or more by retirement. Putting enough money in a savings account or winning the lottery are among them. However, neither of these methods can

Dividend investing is practically always in style. There is nothing quite like getting paid to own shares in a company, and for those who opt to reinvest their dividends, doing so works wonders on

Growth stocks were back in style in 2023 after a disappointing year in 2022. However, not every growth-oriented company kept pace with the broader indexes. Here are two that didn't: Sarepta

Shares of gene sequencing leader Illumina (NASDAQ: ILMN) rallied 36.6% in December, according to data from S&P Global Market Intelligence.

Investors might not be quite so excited, as Illumina

Pharmaceutical giant Pfizer (NYSE: PFE) went through a growth spurt during the COVID-19 pandemic as one of the leading vaccine companies. But the windfall of billions of extra dollars in revenue and

If you're a dividend investor with a leaning toward value investing, you'll want to do a deep dive on Medtronic (NYSE: MDT), Texas Instruments (NASDAQ: TXN), and, perhaps, even Stanley Black &amp

Pfizer (NYSE: PFE) had a disastrous 2023, with its share price collapsing by 44%. It was one of the S&P 500's worst-performing stocks last year. The company's COVID-19 revenue nosedived as the

It isn't unusual for top medical device maker Medtronic (NYSE: MDT) to score regulatory approvals for its goods. Nevertheless, in the healthcare field, nearly any regulatory win is considered a

Investing in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but breaking new ground can sometimes offer outsized rewards. On that note, Editas Medicine (NASDAQ:

Pharmaceutical company AbbVie (NYSE: ABBV) has been a double-deal of price growth and dividend income over the past five years. It achieved 129% in total returns in that time, outpacing the S&P 500.

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered market-beating returns over the past 12 months, five years, and 10 years. Existing shareholders are happy, but those still on the

Income investors love high dividend yields. Unfortunately, those yields often come with unacceptable trade-offs in the form of significant risk and/or low overall growth prospects. That's not always

Investors in AngioDynamics (NASDAQ: ANGO), inventor of the innovative Nanoknife device for electrocuting cancer cells, got an unpleasant shock of their own on Friday morning. Though the company

To say that 2023 was a good year for semiconductor stocks is an understatement. The sector, at least as defined by the VanEck Semiconductor ETF (NASDAQ: SMH), rocketed 73.4% in 2023! So if you had

Investors seeking stocks that can produce dramatic gains in 2024 can find what they're looking for in the biopharmaceutical industry. Clinical-trial results that these two companies are expected to

One of the hallmarks of a diversified portfolio is the inclusion of some dividend stocks. Luckily for investors, there are plenty of dividend-paying companies out there to choose from. They operate

It's never easy to make a list of the "best" of anything, much less stocks to buy. People invest in equities based on various factors that are different from one person to the next and will

Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been

There's a disconnect between AT&T (NYSE: T) the stock and AT&T the company. While investors have punished the telecom stock over the past few years, sending shares down about 30% since the start of